Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$573.9 million.

  • Cytokinetics' Income towards Parent Company fell 18.95% to -$178.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$602.1 million, marking a year-over-year decrease of 7.41%. This contributed to the annual value of -$573.9 million for FY2024, which is 9.43% down from last year.
  • As of FY2024, Cytokinetics' Income towards Parent Company stood at -$573.9 million, which was down 9.43% from -$524.5 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Income towards Parent Company ranged from a high of -$109.9 million in FY2020 and a low of -$573.9 million during FY2024.
  • In the last 3 years, Cytokinetics' Income towards Parent Company had a median value of -$524.5 million in 2023 and averaged -$480.7 million.
  • Data for Cytokinetics' Income towards Parent Company shows a maximum YoY slumped of 84.48% (in 2021) over the last 5 years.
  • Cytokinetics' Income towards Parent Company (Yearly) stood at -$109.9 million in 2020, then slumped by 84.48% to -$202.8 million in 2021, then plummeted by 69.48% to -$343.6 million in 2022, then plummeted by 52.64% to -$524.5 million in 2023, then decreased by 9.43% to -$573.9 million in 2024.